戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 was blocked by atenolol, a selective beta(1)-adrenergic antagonist.
2 tion of a beta(2) (but not beta(1) or alpha) adrenergic antagonist.
3  also delayed by treating mice with an alpha-adrenergic antagonist.
4 duced by therapy with phentolamine, an alpha-adrenergic antagonist.
5      Prazosin is a centrally active alpha(1) adrenergic antagonist.
6 fect was canceled by prior injection of beta-adrenergic antagonists.
7 otine was blocked by prior injection of beta-adrenergic antagonists.
8 tion was further indicated by the effects of adrenergic antagonists.
9 gical differences between these two alpha(2)-adrenergic antagonists.
10 adrenergic antagonist), or zinterol (a beta2-adrenergic antagonist) administered bilaterally into the
11 ntagonist, and yohimbine, a selective alpha2-adrenergic antagonist, also reduced L-NAME-induced const
12 trials in which the combination of an alpha1-adrenergic antagonist and ARI was used to treat symptoma
13 Freshly isolated strips were exposed to beta-adrenergic antagonists and agonists and assayed for cAMP
14 crements are reversed by propranolol, a beta-adrenergic antagonist, and abolished by selective bilate
15  combination of prazosin, a selective alpha1-adrenergic antagonist, and yohimbine, a selective alpha2
16                         The selective beta 1-adrenergic antagonist atenolol (10(-6) M) did not affect
17 l) of either propranolol (a nonspecific beta-adrenergic antagonist), atenolol (a beta1-adrenergic ant
18 of a single injection of the specific alpha2-adrenergic antagonist atipamezole (1.5 mg/kg i.p.) after
19         Consistent with these findings, beta-adrenergic antagonists blocked both the late and the ear
20 ption partially blocked by intrathecal alpha-adrenergic antagonists, but the mechanism underlying thi
21                  We also found that an alpha-adrenergic antagonist can specifically block the QseC re
22 ne epinephrine and show that beta- and alpha-adrenergic antagonists can block the bacterial response
23 ilation of the cerebral vasculature with the adrenergic antagonist carvedilol in a randomized, cross-
24                      Awakening by the alpha2-adrenergic antagonist completely eliminated this interme
25                                         Beta-adrenergic antagonists completely blocked the release of
26        Preinjection of yohimbine, an alpha 2-adrenergic antagonist, completely inhibited this increas
27                 Yohimbine, a specific alpha2-adrenergic antagonist, completely prevented the inductio
28  was administered with and without the alpha-adrenergic antagonist dapiprazole, and its effects were
29             Doxazosin (50 nmol), an alpha(1)-adrenergic antagonist, decreased intercontraction interv
30                  Propranolol, a generic beta-adrenergic antagonist, decreased proliferation of KS-ass
31  receptor antagonist) or propranolol (a beta-adrenergic antagonist) did not alter DA-stimulated clear
32 ed additional inhibitors, including alpha(1)-adrenergic antagonists doxazosin, terazosin, and alfuzos
33 atic hyperplasia can be treated with alpha 1-adrenergic-antagonist drugs that relax prostatic smooth
34 energic agonist, phenylephrine, and a beta-1 adrenergic antagonist, esmolol, in 14 patients with POTS
35                             The use of alpha-adrenergic antagonist for the treatment of pediatric uro
36                              Systemic alpha1-adrenergic antagonists for symptomatic benign prostatic
37             Atipamezole, a selective alpha-2 adrenergic antagonist, given into the LC, 10 microgram/L
38                Propranolol, a nonselective B-adrenergic antagonist, has shown efficacy in decreasing
39 his effect was blocked by use of the beta(2)-adrenergic antagonist ICI 118,551 but not by the alpha-a
40 renol was inhibited completely by the beta 2-adrenergic antagonist ICI-118,551 at 100 nM, with a half
41 ate the physician regarding the use of alpha-adrenergic antagonists in the management of various pedi
42                    The affinities of various adrenergic antagonists in these ocular tissues were comp
43 ystemic co-administration of alpha- and beta-adrenergic antagonists in young (n = 9; 26 +/- 1 years o
44 g evidence suggests that beta-blockers (beta-adrenergic antagonists) increase brain clearance of thes
45 in-deficient and wild-type mice while a beta-adrenergic antagonist increases bone mass in wild-type a
46 ompletely blocked by prior injection of beta-adrenergic antagonists, indicating that beta-adrenergic
47                      Infusions of these beta-adrenergic antagonists into the central nucleus of the a
48 ions in vivo, we show that infusion of alpha-adrenergic antagonists into the NIf (nucleus interfacial
49 icial heart failure treatments, such as beta-adrenergic antagonists, involve improved contractility.
50 r its specific blockade using alpha1/alpha1B adrenergic antagonists led to selective sensitization of
51             These findings suggest that beta adrenergic antagonists may have a therapeutic role in th
52 mprovements in symptoms compared with alpha1-adrenergic antagonist monotherapy after as little as 9 m
53 e evident after 1 year when comparing alpha1-adrenergic antagonist monotherapy and combination medica
54 ean decreases between those receiving alpha1-adrenergic antagonist monotherapy and combination medica
55 therapy demonstrated superiority over alpha1-adrenergic antagonist monotherapy.
56 ce was blocked by pretreatment with the beta-adrenergic antagonist, nadolol (0.5 mg/kg), but not by t
57  adrenergic antagonist, prazosin, an alpha 1-adrenergic antagonist, nor yohimbine, an alpha 2-specifi
58 tic benign prostatic hyperplasia over alpha1-adrenergic antagonist or ARI monotherapy, when prescribe
59                 Nonselective alpha- and beta-adrenergic antagonists or saline were infused in the OB
60                          Treatment with beta-adrenergic antagonists or with S107, a small molecule dr
61 terial infusion of phentolamine (PHEN, alpha-adrenergic antagonist) or phenylephrine (PE, alpha(1)-ad
62 ta-adrenergic antagonist), atenolol (a beta1-adrenergic antagonist), or zinterol (a beta2-adrenergic
63         Presurgical treatment with the alpha-adrenergic antagonist phentolamine completely prevented
64 e, and this increase is blocked by the alpha-adrenergic antagonist phentolamine.
65 h the nonselective alpha-adrenergic and beta-adrenergic antagonists phentolamine and propranolol, or
66                     The application of alpha-adrenergic antagonists (phentolamine or phenoxybenzamine
67 tained presence in the culture of the alpha1-adrenergic antagonist prazosin (Pz) at 10(-7) M.
68 timulation by norepinephrine and an alpha(1)-adrenergic antagonist prazosin is not restored by pertus
69  [Ca2+]i signaling was blocked by the alpha1-adrenergic antagonist prazosin, whereas signaling in the
70 ked by pretreatment of cells with the alpha1-adrenergic antagonist prazosin.
71 opranolol but was not affected by the alpha1-adrenergic antagonist prazosin.
72 ptors since they were blocked by the alpha 1-adrenergic antagonist prazosin.
73 9)-10(-6) m), in the presence of an alpha(1)-adrenergic antagonist, prazosin (10(-6) m), selectively
74          Neither atenolol, a beta 1-specific adrenergic antagonist, prazosin, an alpha 1-adrenergic a
75 renaline release) and phentolamine (an alpha-adrenergic antagonist), profound vasodilatation was seen
76                            Although the beta-adrenergic antagonist propranolol (1) binds at rodent 5-
77                   Administration of the beta-adrenergic antagonist propranolol at encoding abolishes
78 is effect was completely blocked by the beta-adrenergic antagonist propranolol but was not affected b
79                                When the beta-adrenergic antagonist propranolol was added to the stimu
80 (saline, 1, 3, 5 or 10 mg kg(-1) of the beta-adrenergic antagonist propranolol) were trained with a t
81 s (saline, 1, 3, 5 or 10 mg kg-1 of the beta-adrenergic antagonist propranolol) were trained with a t
82 n the NPE but not PE was blocked by the beta-adrenergic antagonist propranolol, the gap junction bloc
83 and these increases were blocked by the beta-adrenergic antagonist propranolol.
84     Moreover, a single injection of the beta-adrenergic antagonist, propranolol, prevented the noctur
85 er, incubation of RG20 cells with the alpha2-adrenergic antagonist rauwolscine or with pertussis toxi
86 Pretreatment with selective beta1- and beta2-adrenergic antagonists reduced the increase in phosphory
87                                       Alpha1-adrenergic antagonists relieve lower urinary tract sympt
88 cycline chemotherapy with adjunctive beta(2)-adrenergic antagonists represents a potential therapeuti
89 denervation models, and propranolol, a beta2-adrenergic antagonist, rescues bone loss.
90  of mice housed at 22 degrees C with a beta2-adrenergic antagonist reverses the norepinephrine-driven
91                                   The alpha2-adrenergic antagonist RX821002 abrogated this effect.
92                                     The beta-adrenergic antagonist sotalol (10-4 M) reduced LL absorp
93  the CPPC model was alleviated by the beta-3 adrenergic antagonist SR59230A.
94 ugh it is the most important target for beta-adrenergic antagonists, such as beta-blockers, relativel
95 usion of dobutamine or treatment with a beta-adrenergic antagonist, suggesting that RLC is constituti
96 ned the effects of administering an alpha-1A-adrenergic antagonist, Tamsulosin, on urodynamics.
97 tenuated by infusion of the selective alpha1 adrenergic antagonist terazosin into the basal forebrain
98                              The hypotensive adrenergic antagonist timolol, propranolol, and betaxolo
99                                     The beta-adrenergic antagonists timolol and propranolol did not s
100 t to the microvessel preparation or an alpha-adrenergic antagonist to the myocytes and was augmented
101 ffect could be reversed by propranolol (beta-adrenergic antagonist) treatment.
102 ved vasoconstriction, phentolamine, an alpha-adrenergic antagonist was administered prior to MA treat
103                        Furthermore, we found adrenergic antagonists were able to slow the rate of the
104 l melatonin formation and is induced by beta-adrenergic antagonists, which block melatonin production
105 in the heart and is the main target for beta-adrenergic antagonists, widely used in the treatment of
106                 Compared with placebo, alpha-adrenergic antagonists will also aid significantly in th
107               OPC-28326 is a selective alpha-adrenergic antagonist with preferential binding to the a
108 nd this suppression was reversed by alpha(2)-adrenergic antagonists with an order of inverse efficacy
109 gn, we orally administered either the alpha2-adrenergic antagonist yohimbine (increasing noradrenergi
110 ic, that of Dex being blocked by the alpha-2 adrenergic antagonist yohimbine, 5 mg/kg, i.p.; that of
111                Pretreatment with the alpha 2-adrenergic antagonist, yohimbine (8 micrograms, I.C.V.),
112 of NE by approximately 30%, whereas alpha(2)-adrenergic antagonist, yohimbine, did not prevent the st

 
Page Top